{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:44:07Z","timestamp":1767015847142,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13000-018-0702-3","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T11:30:23Z","timestamp":1524828623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5121-6325","authenticated-orcid":false,"given":"Yuichiro","family":"Hatano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichirou","family":"Morishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"key":"702_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49\u201356.","journal-title":"J Pathol"},{"key":"702_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"702_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cjp2.53","volume":"2","author":"M Kobel","year":"2016","unstructured":"Kobel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2:247\u201358.","journal-title":"J Pathol Clin Res"},{"key":"702_CR4","doi-asserted-by":"publisher","first-page":"26191","DOI":"10.1038\/srep26191","volume":"6","author":"AJ Cole","year":"2016","unstructured":"Cole AJ, Dwight T, Gill AJ, Dickson KA, Zhu Y, Clarkson A, et al. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep. 2016;6:26191.","journal-title":"Sci Rep"},{"key":"702_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/his.13248","volume":"71","author":"N Singh","year":"2017","unstructured":"Singh N, McCluggage WG, Gilks CB. High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathology. 2017;71:339\u201356.","journal-title":"Histopathology"},{"key":"702_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/modpathol.2016.238","volume":"30","author":"EEK Meserve","year":"2017","unstructured":"Meserve EEK, Brouwer J, Crum CP. Serous tubal intraepithelial neoplasia: the concept and its application. Mod Pathol. 2017;30:710\u201321.","journal-title":"Mod Pathol"},{"key":"702_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/path.3023","volume":"226","author":"E Kuhn","year":"2012","unstructured":"Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol. 2012;226:421\u20136.","journal-title":"J Pathol"},{"key":"702_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamaoncol.2015.1618","volume":"1","author":"AS McDaniel","year":"2015","unstructured":"McDaniel AS, Stall JN, Hovelson DH, Cani AK, Liu CJ, Tomlins SA, et al. Next-generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol. 2015;1:1128\u201332.","journal-title":"JAMA Oncol"},{"key":"702_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","volume":"24","author":"A Yemelyanova","year":"2011","unstructured":"Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011;24:1248\u201353.","journal-title":"Mod Pathol"},{"key":"702_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/modpathol.2014.76","volume":"28","author":"L Jia","year":"2015","unstructured":"Jia L, Yuan Z, Wang Y, Cragun JM, Kong B, Zheng W. Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma. Mod Pathol. 2015;28:118\u201327.","journal-title":"Mod Pathol"},{"key":"702_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/his.13327","volume":"71","author":"MS Anglesio","year":"2017","unstructured":"Anglesio MS, O'Neill CJ, Senz J, Gilks CB, McCluggage WG. Identical TP53 mutations provide evidence that late recurring tubo-ovarian high grade serous carcinomas do not represent new peritoneal primaries. Histopathology. 2017;71:1014\u20137.","journal-title":"Histopathology"},{"key":"702_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13000-016-0585-0","volume":"11","author":"M Furuya","year":"2016","unstructured":"Furuya M, Sato T, Tanaka R, Yamamoto M, Yokota NR, Miyagi E. Metachronous serous endometrial intraepithelial carcinoma and serous peritoneal carcinoma: analysis of probable independent lesions. Diagn Pathol. 2016;11:130.","journal-title":"Diagn Pathol"},{"key":"702_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","volume":"30","author":"F Medeiros","year":"2006","unstructured":"Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230\u20136.","journal-title":"Am J Surg Pathol"},{"key":"702_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/path.2091","volume":"211","author":"Y Lee","year":"2007","unstructured":"Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26\u201335.","journal-title":"J Pathol"},{"key":"702_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J. FIGO committee on gynecologic oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1\u20135.","journal-title":"Int J Gynaecol Obstet"},{"key":"702_CR16","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in Tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33:2457\u201363.","journal-title":"J Clin Oncol"},{"key":"702_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/path.2761","volume":"222","author":"EY Chen","year":"2010","unstructured":"Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube. J Pathol. 2010;222:110\u20136.","journal-title":"J Pathol"},{"key":"702_CR18","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/ncb2344","volume":"13","author":"J Lukas","year":"2011","unstructured":"Lukas J, Lukas C, Bartek J. More than just a focus: the chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol. 2011;13:1161\u20139.","journal-title":"Nat Cell Biol"},{"key":"702_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrrev.2015.07.001","volume":"766","author":"MS Siddiqui","year":"2015","unstructured":"Siddiqui MS, Francois M, Fenech MF, Leifert WR. Persistent gammaH2AX: a promising molecular marker of DNA damage and aging. Mutat Res Rev Mutat Res. 2015;766:1\u201319.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"702_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/PGP.0b013e31829c673b","volume":"33","author":"S Staff","year":"2014","unstructured":"Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, M\u00e4enp\u00e4\u00e4 J. Quantitative analysis of gamma-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Int J Gynecol Pathol. 2014;33:309\u201316.","journal-title":"Int J Gynecol Pathol"},{"key":"702_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13000-017-0605-8","volume":"12","author":"M Zhang","year":"2017","unstructured":"Zhang M, Zhuang G, Sun X, Shen Y, Wang W, Li Q, et al. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. Diagn Pathol. 2017;12:16.","journal-title":"Diagn Pathol"},{"key":"702_CR22","first-page":"517","volume":"123","author":"RG Verhaak","year":"2013","unstructured":"Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123:517\u201325.","journal-title":"J Clin Invest"},{"key":"702_CR23","doi-asserted-by":"publisher","first-page":"dju249","DOI":"10.1093\/jnci\/dju249","volume":"106","author":"GE Konecny","year":"2014","unstructured":"Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014;106:dju249.","journal-title":"J Natl Cancer Inst"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-018-0702-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-018-0702-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-018-0702-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T19:03:39Z","timestamp":1556305419000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-018-0702-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1186\/s13000-018-0702-3","relation":{},"ISSN":["1746-1596"],"issn-type":[{"type":"electronic","value":"1746-1596"}],"subject":[],"published":{"date-parts":[[2018,4,27]]},"assertion":[{"value":"9 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report. A copy of the consent form is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"24"}}